Pharmacokinetic properties of netilmicin in newborn infants. 1979

J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld

Netilmicin and gentamicin susceptibilities of 258 gram-negative organisms and 25 strains of Staphylococcus aureus were nearly identical. The pharmacokinetic properties of netilmicin were evaluated in 101 newborn infants and related to birth weight, gestational age, chronological age, and route of administration. Mean peak serum concentrations of 5.6 to 6.9 and 7.8 to 8.4 mug/ml were observed 30 min after 3- and 4-mg/kg doses, respectively, were given intramuscularly. The peak concentrations were directly related to gestational age. The average serum half-life values varied from 3.4 to 4.7 h and in general were inversely related to birth weight, gestational age, and postnatal age. The pharmacokinetics of netilmicin in 10 infants were similar after intramuscular and intravenous administration. A comparative study of netilmicin and gentamicin in seven neonates revealed greater variability in serum concentrations of gentamicin and a shorter half-life for netilmicin. There was evidence of accumulation of netilmicin in 12 low-birth weight, premature infants who received 4-mg/kg doses for an average of 6.4 days. Serum and urine levels of netilmicin were measured up to 11 days after discontinuation of the drug. These data are well characterized by a two-compartment model. Additional studies of efficacy and long-term toxicity of netilmicin in neonates are necessary.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007232 Infant, Newborn, Diseases Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts. Neonatal Diseases,Disease, Neonatal,Diseases, Neonatal,Neonatal Disease
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009428 Netilmicin Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Certomycin,Netillin,Netilmicin Sulfate,Netrocin,Netromicina,Netromycin,Netromycine,Nétromicine,Sch-20569,Sch 20569,Sch20569
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
May 1984, Antimicrobial agents and chemotherapy,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
April 1985, The Journal of pediatrics,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
June 1984, Pediatria polska,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
July 1977, Antimicrobial agents and chemotherapy,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
January 1985, Archives francaises de pediatrie,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
January 1985, Clinical therapeutics,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
January 1982, The Journal of antimicrobial chemotherapy,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
January 2000, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
November 1989, Drugs,
J D Siegel, and G H McCracken, and M L Thomas, and N Threlkeld
June 2000, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!